Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Starting soon · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Aneurysmal Subarachnoid Hemorrhage
In brief
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Key facts
- Study ID
- NCT07493577
- Run by
- Dr David Hasan, M.D.
- People needed
- 82
- Starts
- 2026-07-23
- Expected to finish
- 2032-01-23
- Last updated by the study team
- 2026-03-25
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke University Health System — Durham, North Carolina, United States
- University of Texas Health Sciences Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.